The strategies employed to target IL-1 signaling include direct inhibition of the IL-1 receptor, selective neutralization of IL-1α or IL-1β ligands with blocking antibodies, and targeted therapies against downstream molecules activated by the IL-1R1/MyD88 complex.235 Anakinra, a recombinant IL-1Ra, has secured FDA approval for rheumatoid arthritis and rare disorders.256 Beyond its established role in inflammatory diseases, anakinra has undergone small-scale clinical trials in solid tumors, exhibiting notable outcomes. Here, IL1B is linked to rheumatoid arthritis.